LENZ Therapeutics' Eye Drop Scores First FDA Approval For Age-Related Blurred Vision Condition Impacting 128 Million People

Presbyopia eye condition

On Thursday, the U.S. Food and Drug Administration approved LENZ Therapeutics, Inc.’s (NASDAQ:LENZ) VIZZ (aceclidine ophthalmic solution, previously known as LNZ100) 1.44%, the first and only FDA-approved aceclidine-based eye drop for presbyopia in adults.

Presbyopia is an age-related vision condition where the eyes gradually lose the ability to focus on nearby objects.